Special populations underrepresented in oncology

Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA
Special populations underrepresented in oncology ( Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA )
4 Apr 2023

PET CT for early-stage malignancies in the Philippines

Dr Marie Dione Sacdalan - ManilaMed, Manila, Philippines
PET CT for early-stage malignancies in the Philippines ( Dr Marie Dione Sacdalan - ManilaMed, Manila, Philippines )
4 Apr 2023

Cancer imaging and its appropriate use in common cancers

Dr Jonas Santiago - St Luke's Medical Center, Manila, Philippines
Cancer imaging and its appropriate use in common cancers ( Dr Jonas Santiago - St Luke's Medical Center, Manila, Philippines )
4 Apr 2023

Online patient advocacy and reliable information sources

Dr Herdee Gloriane Luna - St Luke's Medical Center, Manila, Philippines
Online patient advocacy and reliable information sources ( Dr Herdee Gloriane Luna - St Luke's Medical Center, Manila, Philippines )
4 Apr 2023

The role of curative neoadjuvant treatment in certain cancer types

Dr Arthur Gregory Lui - Metro Davao Medical Research Center, Davao del Sur, Philippines
The role of curative neoadjuvant treatment in certain cancer types ( Dr Arthur Gregory Lui - Metro Davao Medical Research Center, Davao del Sur, Philippines )
4 Apr 2023

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )
22 Mar 2023

Time toxicity: opportunity costs of low value cancer treatment

Dr Christopher Booth - Queen's University, Kingston, Canada
Time toxicity: opportunity costs of low value cancer treatment ( Dr Christopher Booth - Queen's University, Kingston, Canada )
20 Mar 2023

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Mar 2023

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )
16 Mar 2023

Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )
16 Mar 2023